Smith & Nephew Plc Smith & Nephew acquires Atracsys S (0229E)
01 Luglio 2019 - 12:14PM
UK Regulatory
TIDMSN.
RNS Number : 0229E
Smith & Nephew Plc
01 July 2019
Smith & Nephew completes acquisition of optical tracking
technology innovator Atracsys Sàrl
1 July 2019
Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical
technology business, today announces it has completed the
acquisition of Atracsys Sàrl, the Switzerland-based provider of
optical tracking technology used in computer-assisted surgery. The
acquisition supports Smith & Nephew's long-term commitment to
develop its multi-asset digital surgery and robotics ecosystem to
empower surgeons and improve clinical outcomes.
Atracsys' fusionTrack 500 optical tracking camera will be a core
enabling technology for Smith & Nephew's next-generation
robotics platform, due for commercial release in 2020. The
fusionTrack 500 offers superior measurement speed and latency
performance, supporting reduced procedure times, as well as
increased accuracy resulting in finer precision surgical tasks,
such as bone cuts, compared to existing tracking technology.
The commercial terms of the acquisition have not been
disclosed.
ENDS
Enquiries
Investors
Andrew Swift +44 (0) 1923 477433
Smith & Nephew
Media
Charles Reynolds +44 (0) 1923 477314
Smith & Nephew
Charis Gresser/Ayesha Bharmal +44 (0) 207 404 5959
Brunswick
About Smith & Nephew
Smith & Nephew is a portfolio medical technology business
that exists to restore people's bodies, and their self-belief.
Smith & Nephew has leadership positions in Orthopaedics,
Advanced Wound Management and Sports Medicine, more than 16,000
employees and a presence in more than 100 countries. Annual sales
in 2018 were $4.9 billion. Smith & Nephew is a member of the
FTSE100 (LSE:SN, NYSE:SNN). For more information about Smith &
Nephew, please visit our corporate website www.smith-nephew.com and
follow us on Twitter, LinkedIn or Facebook.
Forward-looking Statements
(This document may contain forward-looking statements that may
or may not prove accurate. For example, statements regarding
expected revenue growth and trading margins, market trends and our
product pipeline are forward-looking statements. Phrases such as
"aim", "plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.)
(Trademark of Smith & Nephew. Certain marks registered US
Patent and Trademark Office.)
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ACQBFLFBKDFFBBB
(END) Dow Jones Newswires
July 01, 2019 06:14 ET (10:14 GMT)
Grafico Azioni Smith & Nephew (LSE:SN.)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Smith & Nephew (LSE:SN.)
Storico
Da Apr 2023 a Apr 2024